Product description

The Invesco NASDAQ Biotech UCITS ETF Acc aims to provide the performance of the NASDAQ Biotechnology Index, after fees. The index comprises biotechnology and pharmaceuticals companies (as defined by ICB) listed on the NASDAQ Stock Market.  Stocks are filtered to meet minimum market capitalisation and liquidity requirements. They are then weighted by modified market capitalisation: the largest five constituents are capped at 8%; the remaining constituents are capped at 4%. The index is rebalanced quarterly and reviewed annually in December.

Please note that, prior to 25 May 2018, the name of this product was Source NASDAQ Biotech UCITS ETF. This change has no bearing on the investment objective or any other aspect of the product.

Trading information

London Stock Exchange
Trading currency USD
Settlement period T+2
Exchange ticker SBIO
Bloomberg ticker SBIO LN
Bloomberg iNAV SBIOIN
Reuters ticker SBIO.L
Reuters iNAV 0J1KINAV.DE
WKN A12CCJ
Valor 25524842
Sedol BQY79Y5
Today (16 Jul 2018)
Bid price Loading...
Offer price Loading...
iNAV Loading...
Last update Loading...
SIX Swiss Exchange
Trading currency USD
Settlement period T+2
Exchange ticker SBIO
Bloomberg ticker SBIO SW
Bloomberg iNAV SBIOIN
Reuters ticker SBIO.S
Reuters iNAV 0J1KINAV.DE
WKN A12CCJ
Valor 25524842
Today (16 Jul 2018)
Bid price Loading...
Offer price Loading...
iNAV Loading...
Last update Loading...
Euronext Amsterdam
Trading currency EUR
Settlement period T+2
Exchange ticker SBIO
Bloomberg ticker SBIO NA
Bloomberg iNAV SBIOINE
Reuters ticker SBIO.AS
Reuters iNAV 0J1JINAV.DE
WKN A12CCJ
Today (16 Jul 2018)
Bid price Loading...
Offer price Loading...
iNAV Loading...
Last update Loading...

Key information

Bloomberg ticker SBIO LN
ISIN IE00BQ70R696
Benchmark BBG ticker XNBI
Management fee 0.40%
Swap fee 0.00%
NAV (12 Jul 2018) $37.78
AUM $475,575,347
Base currency USD

Key fund risks

Counterparty risk:  Other financial institutions provide services such as safekeeping of assets or as a counterparty to financial contracts such as derivatives. The Fund is exposed to the risk of bankruptcy, or any other type of default of the counterparty related to any trading transaction entered into by the Fund.

Risk of using derivatives:  in order to reach its investment objective, the Fund enters into swap agreements which provide the performance of the Reference Index, and may imply a range of risks which could lead to an adjustment or even the early termination of the swap agreement.

Liquidity on secondary market risk:  Lower liquidity means there are insufficient buyers or sellers to allow the Fund to sell or buy investments readily. On-exchange liquidity may be limited due to Reference Index suspension, a decision by one of the relevant stock exchanges, or a breach by the market maker of respective stock exchange requirements and guidelines. 

 

 

The performance information on this web page refers to past performance. Past performance is not a reliable indicator of future returns.

The data shown on this page is not real-time, i.e. it may be delayed due to mandatory requirements of the data provider. As a consequence, the price of the product linked to a specific underlying you are quoted by your broker or intermediary may substantially differ from the price of the product that you would expect on the basis of the data displayed on this site. Invesco UK Services Limited accepts no responsibility for loss, however caused, resulting from errors in this data.

ETF performance is in the fund’s base currency, includes dividends, reinvested. ETF performance is Net Asset Value after management fees and other ETF costs but does not consider any commissions or custody fees payable when buying, holding or selling the ETF. The ETF does not charge entry or exit fees. Data: Invesco.